Q2 FY2026 · ended Jun 30, 2026 · Revenue $0 · Filed Jul 14, 2026
Beacon Topco, Inc. (CLYD) files with the SEC under industry code 2834, Pharmaceutical Preparations. In Q2 of fiscal 2026, the quarter ended Jun 30, 2026, it reported revenue of $0 and net income of $0.
Revenue
$0
Net income
$0
Operating cash flow
$0
Free cash flow
—
EPS
—
Dividend per share
None
Shares outstanding
100
+0.0% vs prior quarter
Net cash
—
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- CLYD
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Germantown, MD
- SEC filer status
- , Emerging growth company
- SEC CIK
- 2094256
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
|---|---|
| Revenue | $0 |
| Net income | $0 |
| Operating cash flow | $0 |
| Total assets | $0 |
| Total liabilities | $0 |
| Cash and investments | $0 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Material agreement
|
Nov 5, 2026 | Oct 31, 2026 |
| 8-K |
Current report
Material agreement, Other events
|
Sep 24, 2026 | Sep 22, 2026 |
| 8-K |
Current report
Change to shareholder rights, Bylaw or fiscal year change
|
Sep 17, 2026 | Sep 15, 2026 |
| 10-Q | Quarterly report | Jul 14, 2026 | Jun 30, 2026 |
| 10-Q | Quarterly report | Jun 5, 2026 | Mar 31, 2026 |
All 18 Beacon Topco, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.